NASDAQ:TNXP Tonix Pharmaceuticals Q1 2026 Earnings Report $9.70 -0.54 (-5.27%) Closing price 04:00 PM EasternExtended Trading$9.82 +0.12 (+1.22%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tonix Pharmaceuticals EPS ResultsActual EPS-$2.93Consensus EPS -$2.54Beat/MissMissed by -$0.39One Year Ago EPSN/ATonix Pharmaceuticals Revenue ResultsActual Revenue$6.88 millionExpected Revenue$6.13 millionBeat/MissBeat by +$753.00 thousandYoY Revenue GrowthN/ATonix Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time7:00AM ETUpcoming EarningsTonix Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tonix Pharmaceuticals Earnings HeadlinesTonix Pharmaceuticals Holding Corp (TNXP)September 23 at 5:57 PM | in.investing.comTonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®September 22 at 10:30 AM | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 24 at 1:00 AM | Decentralized Masters (Ad)Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®September 22 at 7:00 AM | globenewswire.comVoyager Therapeutics (NASDAQ:VYGR) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head to Head AnalysisSeptember 21 at 6:14 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)September 16, 2026 | theglobeandmail.comSee More Tonix Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email. Email Address About Tonix PharmaceuticalsTonix Pharmaceuticals (NASDAQ:TNXP) is a biopharmaceutical company focused on developing therapies and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company’s programs use a range of approaches, including small-molecule medicines, biologics, vaccines, and intranasal therapies. Tonix’s development portfolio has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for fibromyalgia and other pain-related conditions. The company has also pursued candidates such as TNX-1900, an intranasal oxytocin-based therapy being studied for neuropsychiatric and metabolic disorders, as well as vaccine programs including TNX-801, a vaccine candidate for smallpox and mpox. Founded in 2007, Tonix Pharmaceuticals is headquartered in Chatham, New Jersey. The company’s research and development activities are primarily conducted in the United States, with programs intended for potential use in global markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.View Tonix Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
